<DOC>
	<DOCNO>NCT02782845</DOCNO>
	<brief_summary>This study assess prophylactic effect pegfilgrastim ( Neulastim ) febrile and/or Grade IV neutropenia participant receive chemotherapy ( CT ) immunochemotherapy ( ICT ) first second line treatment NHL . Pegfilgrastim administer fix dose 6 milligram ( mg ) subcutaneously 24 hour last dose CT ICT treatment cycle .</brief_summary>
	<brief_title>An Expanded Access Program Pegfilgrastim ( Neulastim ) Participants With Non-Hodgkin 's Lymphoma ( NHL )</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<criteria>NHL support Immunohistochemical report Eastern Cooperative Oncology Group ( ECOG ) performance status great equal ( &gt; /= ) 2 Total serum bilirubin le ( &lt; ) 2 time upper limit normal ( ULN ) Absolute neutrophil count ( ANC ) great ( &gt; ) 2 x10^9 per liter ( /L ) Bone marrow compromise &gt; 10 percent ( % ) Any malignant myeloid condition Active infection require systemic antiinfectious therapy ( antibiotic , antifungal drug , antiviral drug ) within 72 hour prior CT ICT initiation Known hypersensitivity reaction Escherichia coli derive product Pregnant nursing participant . Women childbearing potential use safe contraceptive method</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>